REGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Other Events
Item8.01.
| Other Events. |
On April26, 2017, REGENXBIO Inc. (the Company) issued a press
release announcing that the underwriters of its previously
announced public offering of common stock, which initially closed
on March27, 2017, have exercised their option to purchase an
additional 555,000 shares of the Companys common stock. The
aggregate net proceeds to the Company in connection with the
offering are expected to be approximately $81.5 million, after
deducting underwriting discounts and commissions and estimated
offering expenses.
A copy of the press release is filed as Exhibit 99.1 to this
Current Report on Form 8-K and incorporated herein by reference.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
ExhibitNo. |
Description |
|
| 99.1 | REGENXBIO Inc. Press Release dated April26, 2017. |
About REGENXBIO INC. (NASDAQ:RGNX)
REGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP). REGENXBIO INC. (NASDAQ:RGNX) Recent Trading Information
REGENXBIO INC. (NASDAQ:RGNX) closed its last trading session up +0.30 at 21.20 with 341,095 shares trading hands.
